Drug development plans that aren’t fully aligned across clinical, regulatory, and operational teams introduce costly delays, rework, and regulatory risk. Certara’s integrated planning approach helps you break down silos and build coordinated, data-driven strategies that strengthen milestones from early development through regulatory engagement.
Integrate your drug development strategy with Certara
See how strategic alignment across functions accelerates decisions and reduces risk.
With Certara experts you get:
Cross-functional alignment across clinical, regulatory, and operational teams
Data-driven development strategies that strengthen key milestones
Improved submission readiness and regulatory confidence
Clearer assumptions, timelines, and evidence plans across your program
Why you shouldn’t miss this opportunity
Even small efficiency gains can create significant enterprise value. Research shows that just a 3% increase in process efficiency can represent up to $300 million in potential savings per drug.
This session will help you evaluate where earlier, better-informed decisions can reduce waste and unlock value across your portfolio.
- Identify inefficiencies that may be costing time and capital
- Turn fragmented processes into measurable efficiency gains
- Optimize resources toward your highest-value programs
- Strengthen regulatory readiness through aligned evidence planning
- Accelerate innovative medicines to patients with greater confidence
早期開発にサターラが選ばれる理由
700
700人の医薬品開発の専門家が、最新テクノロジーを駆使して、貴社の開発を力強くサポートします。
>90
2014年以降に米国FDAで承認された新薬の90％は、サターラのテクノロジーを活用したソリューションによって支援されています。
400
MD、PharmD、PhDを保有するコンサルタントの数
7
サターラの研究者のうち7名が、被引用数で世界上位2％にランクインしています。
